Archaeosomes and Gas Vesicles as Tools for Vaccine Development
Open Access
- 10 September 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Archaea are prokaryotic organisms that were classified as a new domain in 1990. Archaeal cellular components and metabolites have found various applications in the pharmaceutical industry. Some archaeal lipids can be used to produce archaeosomes, a new family of liposomes that exhibit high stability to temperatures, pH and oxidative conditions. Additionally, archaeosomes can be efficient antigen carriers and adjuvants promoting humoral and cellular immune responses. Some archaea produce gas vesicles, which are nanoparticles released by the archaea that increase the buoyancy of the cells and facilitate an upward flotation in water columns. Purified gas vesicles display a great potential for bioengineering, due to their high stability, immunostimulatory properties and uptake across cell membranes. Both archaeosomes and archaeal gas vesicles are attractive tools for the development of novel drug and vaccine carriers to control various diseases. In this review we discuss the current knowledge on production, preparation methods and potential applications of archaeosomes and gas vesicles as carriers for vaccines. We give an overview of the traditional structures of these carriers and their modifications. A comparative analysis of both vaccine delivery systems, including their advantages and limitations of their use, is provided. Gas vesicle- and archaeosome-based vaccines may be powerful next-generation tools for the prevention and treatment of a wide variety of infectious and non-infectious diseases.Funding Information
- Narodowym Centrum Nauki
This publication has 47 references indexed in Scilit:
- Synthetic Archaeosome Vaccines Containing Triglycosylarchaeols Can Provide Additive and Long-Lasting Immune Responses That Are Enhanced by ArchaetidylserineArchaea, 2012
- In vitro assessment of halobacterial gas vesicles as a Chlamydia vaccine display and delivery systemVaccine, 2012
- RD Antigen Based Nanovaccine Imparts Long Term Protection by Inducing Memory Response against Experimental Murine TuberculosisPLOS ONE, 2011
- Archaeosomes with encapsulated antigens for oral vaccine deliveryVaccine, 2011
- Intranasal Immunization with an Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery Formulation Protects against a Respiratory Pathogen ChallengePLOS ONE, 2010
- Archaeosome Adjuvant Overcomes Tolerance to Tumor-Associated Melanoma Antigens Inducing Protective CD8+T Cell ResponsesJournal of Immunology Research, 2010
- Towards an understanding of the adjuvant action of aluminiumNature Reviews Immunology, 2009
- Cassette-based presentation of SIV epitopes with recombinant gas vesicles from halophilic archaeaJournal of Biotechnology, 2004
- Halocins and sulfolobicins: The emerging story of archaeal protein and peptide antibioticsJournal of Industrial Microbiology & Biotechnology, 2002
- Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Mediated, and Memory Responses: Comparison to Conventional Liposomes and AlumInfection and Immunity, 2000